Journals / Erciyes Tıp Dergisi / 2003 / Cilt: 25 - Sayı: 3

Bone mineral density in patients with multiple sclerosis

Multipl sklerozlu olgularda kemik mineral yoğunluğu

Pages
131–136
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was suggested that steroid use was a significant cause of low BMD in this population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Patients with multiple sclerosis (MS) are at risk for osteoporosis because of immobility and corticosteroid use.
📊
Key Findings & Data:Patients and method: Forty-two patients with MS (10 male, 32 female) and 28 (7male, 21 female) controls were enrolled into the study.
💡
Conclusion & Impact:It was suggested that steroid use was a significant cause of low BMD in this population.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Patients with multiple sclerosis (MS) are at risk for osteoporosis because of immobility and corticosteroid use. The aim of this study was to determine the factors affecting bone mineral density (BMD) in MS patients. Patients and method: Forty-two patients with MS (10 male, 32 female) and 28 (7male, 21 female) controls were enrolled into the study. BMD and bone turn-over markers (serum calcium, phosphorus, alkaline phosphatase, osteocalcin and urine calcium, creatinine, deoxypyridinoline) were evaluated. Results: Bone turn-over markers were similar in both groups. BMD were signiflcantly lower in MS patients compared to the control group (p=0.001). There was no correlation between functional status of the patients that were evaluated by expanded disability status scale (EDSS) and BMDs (r=0.128). No correlation was found between diagnosis duration of the disease and BMDs (r=0.183). Femoral and lumbar BMD were significantly lower in patients receiving steroids when compared with patients who have not received steroids; however, there was no correlation between different steroid doses and BMDs. Conclusion: In our study, no correlation was found between BMD and duration of the disease or disability. But, since our all patients were ambulatory, it was impossible to evaluate whether there was a relationship between disability and BMD. Corticosteroids used for treatment of MS are found to be important risk factor for osteoporosis in MS patients. It was suggested that steroid use was a significant cause of low BMD in this population.

Özet

Amaç: Multipl sklerozlu(MS) hastalar immobilite ve kortikosteroid kullanımları nedeni ile osteoporoz için risk altındadırlar. Bu çalışmanın amacı MS'Ii hastalarda kemik mineral yoğunluğunu (KMY) etkileyen faktörleri araştırmaktı. Hastalar ve yöntem: Çalışmaya 42 MS' Ii ( 10 erkek, 32 kadın) hasta ve 28 kontrol olgusu (7 erkek, 21 kadın) alındı. KMY'leri ve kemik döngüsü markırlan (serum kalsiyum, fosfor, alkalen fosfataz, osteokalsin, idrar Ca, kreatininye deoksipridinolin) değerlendirildi. Bulgular: Kemik döngüsü markırlan her iki grupta da benzerdi. KMY'leri MS'li hastalarda kontrol grubuna göre anlamlı derecede düşüktü (p>0.05). MS'li hastaların fonksiyonel durumlarını değerlendirmek için kullanılan genişletilmiş özürlülük skalası (EDSS) skoru ile KMY arasında ilişki bulunamadı (r=0.128). Yine hastalığın tanı süresi ile KMY arasında ilişki yoktu (r=0.183). Kortikosteroid kullanan hastaların KMY, steroid kullanmamış hastalarınkinden anlamlı derecede düşüktü. Fakat farklı kümülatif kortikosteroid dozları ile KMY'leri arasında ilişki bulunamadı. Sonuç: Bizim sonuçlarımızda KMY ile hastalığın tanı süresi ve özürlülük derecesi arasında ilişki saptanmadı. Fakat tüm hastalarımızın ambulatuar olması, özürlülük ve KMY arasında ilişkinin yorumlanmasını engellemektedir. MS'de kortikosteroid kullanımının osteoporoz gelişimi için önemli bir risk faktörü olduğu bulundu. Steroidin bu populasyonda KMY azaltan önemli bir sebep olduğu sonucuna varıldı.

🔖

Cite This Article

LEVENDOĞLU, F., AKPINAR, Z., TOKGÖZ, S. (2022). Bone mineral density in patients with multiple sclerosis. Erciyes Tıp Dergisi, Cilt: 25 - Sayı: 3, 131–136. https://ajindex.com/articles/502878

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Prryse WP, Costello F. The epidemiology of multiple sclerosis. In:Cook SD (ed), Handbook of Multiple Sclerosis. Marcel Dekker, New York 2001, pp15-32
  2. Gökçe-Kutsal Y. Osteoporoz. In:Beyazova M, Gökçe-Kutsal Y (eds), Fiziksel Tıp ve Rehabilitasyon Kitabı. Güneş Kitabevi. Ankara 2000, pp1872-1893
  3. Yılmaz C. Osteoporozun etyopatogenezi. In: Yılmaz C (ed), Osteoporoz. Bilimsel Tıp Yayınevi, Ankara 1997: pp30-50
  4. Favus JM, Christakos S, Kleerekoper M, et al. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. (2nd ed). Lippincott-Raven, Philadelphia 1993, pp 83- 152. 5. delPuente A, Pappone N, Mandes MG, Mantova D, Scadpa R, Oriente P. Determinants of bone mineral density in immobilization: a study on hemiplegic patients. Osteoporos Int. 1996;6:50-54
  5. Quesada- Gomez JM, Alonso J and Bouillon R. Vitamin D insufficiency as a determinant of hip fractures. Osteoporosis Int 1996; Suppl. 3: 42- 47
  6. Cosman F, Nieves J, Komar L, et al. Fracture history and bone loss in patients with MS. Neurology 1998;51:1161-1165
  7. Formica CA, Cosman F, Nieveas J, Herbert J, Lindsay R. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use. Caicif Tissue Int. 1997;61:129-133
  8. Tüzün Ş, Altıtaş A, Karacan İ, et al. Multipl sklerozlu olgularda kemik mineral yoğunluğunu etkiyelen faktörlerin irdelenmesi. Türkiye Fiziksel Tıp ve Reh Dergisi 2000;3:27- 33
  9. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994; 44:1687-1692
  10. Lucas K, Hohfeld R. Differential aspects of cytokines in the immunopathology of MS. Neurology 1995, 45:4-5
  11. Urist MR, Hudak RT, Huo YK,Rasmussen JK. Osteoporosis:a bone morphogenetic protein auto-immune disorder. Prog Clin Biol Res 1985;187:77-96
  12. Poser CM, Paty DW, Scheinberg L, et al. New diagnositc criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
  13. Kurtzke J. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983, 33: 1444-1452
  14. Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986; 314:1676-86 16. Mazess RB and Whedon D. Immobilization and bone. Calcif Tissue Int. 1983; 35:265-267
  15. Roberts D, Lee W, Cuneo RC,Witmann J et al. Longitıdinal study of bone turnover after acute spinal cord injury. J Clin. Endocrin and Metab.